Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Bausch + Lomb (Abbreviated New Drug Application)

M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Rights to an abbreviated new drug application (ANDA). The ANDA rights concern Nystatin Oral suspension, a treatment for candidiasis in the oral cavity.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Acquirer
Hi-Tech Pharmaceuticals
Primary Office
  • 1400 North Goodman Street
  • Rochester, NY 14609
  • United States

Bausch + Lomb (Abbreviated New Drug Application) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Bausch + Lomb (Abbreviated New Drug Application)‘s full profile, request access.

Request full access to PitchBook

Bausch + Lomb (Abbreviated New Drug Application) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Bausch + Lomb (Abbreviated New Drug Application)‘s full profile, request access.

Request full access to PitchBook